C. Grohé

发表

OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

M. Tsuboi, R. Herbst, Yi-long Wu, 2021 .

LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

M. Tsuboi, Jie He, R. Herbst, 2020 .

Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment

C. Kropf-Sanchen, H. Watz, J. Ficker, 2022, Scientific Reports.

The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort

C. Kropf-Sanchen, H. Watz, J. Virchow, 2019, Respiratory Research.

Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives.

R. Kaiser, S. Novello, W. Brueckl, 2023, Lung cancer.

Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).

N. Reinmuth, A. Bleckmann, M. Reck, 2023, Clinical lung cancer.

Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.

T. Blum, D. Misch, J. Kollmeier, 2023, Lung cancer.

1300PDImpact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine

R. Riedel, J. Wolf, R. Büttner, 2017 .

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2023, The New England journal of medicine.

Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis.

C. Grohé, H. Vetter, S. Kahlert, 1998, The Journal of endocrinology.

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

A. Drilon, S. Ou, M. Ahn, 2020 .

Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry

A. Prasse, W. Gesierich, M. Kreuter, 2023, BMC Pulmonary Medicine.

Estrogen modulates AT1 receptor gene expression in vitro and in vivo.

S. Rosenkranz, M. Daemen, F. Beckers, 1998, Circulation.

Malignant thymoma: current status of classification and multimodality treatment

D. Huhn, H. Müller-Hermelink, J. Rockstroh, 2003, Annals of Hematology.

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

C. Schumann, T. File, P. Eckburg, 2011, The Journal of antimicrobial chemotherapy.

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of Clinical Oncology.

Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study

S. Sherman, S. Murray, P. Lazure, 2023, BMC Medical Education.

Toll‐like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis

A. Gillissen, C. Grohé, G. Baumgarten, 2006, Clinical and experimental immunology.

[Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010].

A. Günther, H. Ghofrani, F. Reichenberger, 2010, Deutsche medizinische Wochenschrift.

[Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2010].

H. Schäfers, F. Langer, M. Hoeper, 2010, Deutsche medizinische Wochenschrift.

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy

C. Grohé, P. Velling, D. Skowasch, 2011, European journal of medical research.

Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.

S. Krüger, S. Hammerschmidt, T. Wehler, 2023, Journal of Clinical Oncology.

17&bgr;-Estradiol regulates nNOS and eNOS activity in the hippocampus

H. Vetter, K. Fink, R. Meyer, 2004, Neuroreport.

Diagnostik und Therapie der kardialen Sarkoidose

B. Meder, C. Grohé, D. Skowasch, 2019, Pneumologie.

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Roman K. Thomas, T. Zander, D. Seidel, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic and geographic influence on phenotypic variation in European sarcoidosis patients

J. Milanowski, A. Prasse, J. Strausz, 2023, Frontiers in medicine.

Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study

S. Sherman, S. Murray, P. Lazure, 2023, Thyroid Research.

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).

J. Neal, H. Wakelee, R. Herbst, 2023, Journal of Clinical Oncology.

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial

C. Kropf-Sanchen, P. Schnabel, W. Engel-Riedel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

D. Planchard, J. Rotow, Yi‐Long Wu, 2024, Frontiers in oncology.

Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.

J. Neal, T. Patil, Z. Piotrowska, 2024, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Nisoldipine on Endothelin‐1— and Angiotensin II‐Induced Immediate/Early Gene Expression and Protein Synthesis in Adult Rat Ventricular Cardiomyocytes

L. Neyses, Hans-Jürgen Vetter, J. Nouskas, 1994, Journal of cardiovascular pharmacology.

Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD—results from COSYCONET

C. Kropf-Sanchen, F. Biertz, S. Söhler, 2024, Respiratory research.

Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

T. Blum, C. Grah, N. Suttorp, 2019, Annals of Oncology.